-+ 0.00%
-+ 0.00%
-+ 0.00%
Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity
Share
Listen to the news
  • Encouraging tolerability profile with stomatitis as the only dose-limiting toxicity; low overall hematologic toxicity, consistent with low circulating free-exatecan levels, supporting linker stability
  • Antitumor activity observed across tumor types, including in post-enfortumab vedotin urothelial cancer; ORR of 33% (2/6) at the maximum tolerated dose of 3.6 mg/kg Q3W in non-urothelial tumors
  • Initiating dose optimization with first patient planned in H1 2027, to further characterize safety and activity in post-EV urothelial cancer at upper dose levels and define a recommended Phase 2 dose and schedule
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending